Clinical Scorecard: Curbing Drug-Related Halitosis for Closer Moments
At a Glance
| Category | Detail |
|---|---|
| Condition | Drug-related halitosis |
| Key Mechanisms | Intra-oral and extra-oral sources related to drug-induced xerostomia and medication-related osteonecrosis of the jaw. |
| Target Population | Individuals taking medications associated with halitosis. |
| Care Setting | Dental and clinical settings. |
Key Highlights
- Halitosis prevalence estimated between 2.4% to 78%, with systematic reviews suggesting around one-third of the population.
- Drugs causing xerostomia include anticholinergics, antidepressants, and various other medications.
- Extra-oral halitosis can result from drugs like ranitidine, antifungals, and nonsteroidal anti-inflammatory drugs.
- Dental evaluations can help identify intra-oral sources of halitosis.
- Improving oral health and hygiene can mitigate halitosis before social interactions.
Guideline-Based Recommendations
Diagnosis
- Identify medications that may cause halitosis.
- Conduct dental evaluations to assess intra-oral health.
Management
- Implement oral hygiene techniques and treatments for xerostomia.
- Use therapeutic mouthwashes with antimicrobial ingredients.
Monitoring & Follow-up
- Regular dental check-ups to manage oral health.
Risks
- Social, psychological, and emotional impacts of halitosis.
Patient & Prescribing Data
Individuals on medications known to cause halitosis.
Awareness of drug-related risks can aid in effective management.
Clinical Best Practices
- Prioritize dental evaluations for patients on high-risk medications.
- Educate patients on the importance of oral hygiene and hydration.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
